Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 04, 2022

SELL
$3.2 - $5.69 $475,840 - $846,103
-148,700 Reduced 42.56%
200,700 $26,000
Q1 2022

Apr 14, 2022

BUY
$2.8 - $7.39 $978,319 - $2.58 Million
349,400 New
349,400 $13,000

Others Institutions Holding EQRX

About EQRx, Inc.


  • Ticker EQRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 448,140,992
  • Description
  • EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...
More about EQRX
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.